{"id":"NCT01145638","sponsor":"Pharmacosmos A/S","briefTitle":"A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)","officialTitle":"A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2014-04","completion":"2014-05","firstPosted":"2010-06-16","resultsPosted":"2015-12-03","lastUpdate":"2015-12-03"},"enrollment":350,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-myeloid Malignancies","Chemotherapy Induced Anaemia"],"interventions":[{"type":"DRUG","name":"iron isomaltoside 1000","otherNames":["Monofer"]},{"type":"DRUG","name":"iron sulphate","otherNames":["Ferroduretter"]}],"arms":[{"label":"iron isomaltoside 1000","type":"EXPERIMENTAL"},{"label":"iron sulphate","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.","primaryOutcome":{"measure":"Change in Hb Concentration","timeFrame":"Baseline week 4","effectByArm":[{"arm":"Iron Isomaltoside 1000","deltaMin":0.48,"sd":null},{"arm":"Iron Sulphate","deltaMin":0.44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["India"]},"refs":{"pmids":["26927900"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":229},"commonTop":["Anaemia","Alopecia","Asthenia","Vomiting","Leukopenia"]}}